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Familial hypercholesterolaemia remains largely 
unrecognised and undertreated in Australian 
primary care. A new approach involving increased 
awareness, early detection, lifelong treatment and 
cascade testing of relatives is essential to improve 
outcomes of patients with this disorder.
F amilial hypercholesterolaemia (FH) is a  relatively common, autosomal dominant, inherited disorder of lipid metabolism1 that can cause atherosclerosis, premature coro-
nary artery disease (CAD) and early death if left 
untreated. The significance of FH is generally not 
well appreciated among GPs and patients in the 
Australian community, with the result that most 
affected  individuals remain undiagnosed, while 
many who are detected are often inadequately 
treated.2 The condition is caused by a defect in the 
LDL-receptor pathway and results in elevated total 
and low density lipoprotein cholesterol (LDL-c) levels 
in the bloodstream from birth. The increased lifelong 
exposure to LDL-c accelerates the atherosclerotic process.1
As FH is autosomal dominant, children of affected individuals 
have a 50% chance of inheriting the condition.1 For males with 
FH, the risk of developing CAD before age 50 years is 50%, 
whereas for females it is 30% before age 60 years.3 As people with 
FH are already at very high risk, the use of cardiovascular disease 
(CVD) risk calculators to assess absolute risk in FH patients is 
not appropriate.4 The marked acceleration of coronary athero-
sclerosis in people with FH means that young patients with FH 
have much to gain from early diagnosis and treatment. Effective 
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  KEY POINTS
• Familial hypercholesterolaemia (FH) is a relatively
common inherited disorder of high cholesterol levels.
• FH can lead to atherosclerosis, premature coronary artery
disease and early death if left untreated.
• Cascade testing of relatives of patients with FH is cost-
effective and necessary as one in two will have the
condition.
• Innovations in primary care can improve FH detection in
the community.
• An integrated approach to FH detection involving GPs,
specialists and pathology laboratories is recommended.
• Primary care teams are well positioned to provide a
sustainable approach to FH diagnosis and management
but greater awareness of this condition is needed.
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and early treatment of FH with statin therapy reduces the lifetime 
exposure to very high cholesterol levels with the concomitant 
reduction in CAD events largely offsetting the cost of prolonged 
treatment.5 It is important therefore for doctors and patients to 
appreciate the need to detect and treat FH as early as possible.6
In the past, the prevalence for FH was generally reported to 
be one in 500,1 but more recent research suggests it is more com-
mon (about one in 200 to 300),7-9 especially among populations 
exhibiting founder gene effects. Genetic testing has previously 
been the diagnostic gold standard, but it is now known that 
inheriting multiple less common mutations in many genes can 
cause similar functional consequences.10 A mutation is currently 
detected in 60 to 90% of individuals with FH.2 An alternative and 
complementary approach is to use a clinical tool such as the Dutch 
Lipid Clinic Network Criteria (DLCNC) score to make the diag-
nosis (Table),11 and this pragmatic approach is now recommended 
for use in the Australian primary care setting.4,12
Primary care based innovations 
The consensus statement of the European Atherosclerosis Society 
and integrated guidance from the International FH Foundation 
is that treatment for FH should be in primary care and preferably 
in a family context.2,6 They advise that more complex cases and 
children with FH should be referred to specialist lipid or FH 
clinics. The Netherlands and Norway lead the way in the world 
for having identified the greatest proportion of individuals 
TABLE. DUTCH LIPID CLINIC NETWORK CRITERIA (DLCNC)  
FOR MAKING A CLINICAL DIAGNOSIS OF FAMILIAL 
HYPERCHOLESTEROLAEMIA (FH) IN ADULT INDEX CASES11
Criteria Score 
Family history
First-degree relative with known premature coronary 
and/or vascular disease (men aged <55 years, 
women aged <60 years)
OR
First-degree relative with known LDL-cholesterol level 
above the 95th percentile for age and gender*
1
First-degree relative with tendinous xanthomata  
and/or arcus cornealis
OR
Children aged <18 years with LDL-cholesterol level 
above the 95th percentile for age and gender*
2
Clinical history
Patients with premature coronary artery disease 
(men aged <55 years, women aged <60 years)
2
Patients with premature cerebral or peripheral 





Arcus cornealis before 45 years of age 4
Investigation
LDL-cholesterol (mmol/L)
      8.5 or above 8
      6.5 to 8.4 5
      5.0 to 6.4 3
      4.0 to 4.9 1
Diagnosis Total
Definite FH >8
Probable FH 6 to 8 
Possible FH 3 to 5 
Unlikely FH <3
* Supporting documentation for the manual calculation of the Dutch Lipid Clinic 
Network Score (DLCNS) is available online at: http://www.athero.org.au/wp-content/
uploads/2015/02/Supporting-Documentation-for-the-manual-calculation-of-DLCNS.
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estimated to have FH, with 71% and 43% 
of those with FH in the two countries, 
respectively, estimated to have been 
detected.2 More recently, the UK has begun 
to improve detection and management of 
FH by establishing the NHS Clinical 
Genetics in Primary Care initiative,13 and 
also through establishing a network of 
regional specialist lipid clinics that are 
available to support primary care 
management.14
The importance of developing an 
acceptable approach to increase detection 
and diagnosis of index cases for FH at the 
primary care level in Australia is partly 
recognised.12 A combined opportunistic 
and retrospective approach needs to be 
evaluated to ascertain acceptance for 
patients, GPs, practice nurses, nurse prac-
titioners and practice reception staff.
Central to FH care is identification of 
the index case (the first individual 
 identified with FH in a family). Data 
extraction tools can be used to examine 
the electronic medical record base in pri-
mary care practices. This can help iden-
tify patients at higher risk of FH and can 
be combined with family history and 
physical examination findings to establish 
a phenotypic diagnosis. 
An alternative approach to detecting 
FH is for the laboratory to highlight 
opportunistically individuals at high risk 
of FH based on their LDL-c results.15 The 
laboratory may alert the requester that 
their patient is at risk of FH by adding an 
interpretative comment to the lipid result, 
which has been shown to be associated 
with greater reductions in LDL-c sub-
sequently being achieved.16 A phone call 
between the chemical pathologist and 
the requester has been associated with 
 significant improvements in FH detection 
for individuals at high risk.17
The DLCNC score encompasses LDL-c 
concentration; family and personal history 
of premature coronary artery and/or 
 vascular disease; family history of raised 
LDL-c; and physical examination to detect 
tendon xanthomata or premature arcus 
cornealis (Figures 1 and 2). It is important 
to consider and exclude secondary causes 
of hypercholesterolaemia, such as liver or 
renal disease, corticosteroid use or hypo-
thyroidism, before making a phenotypic 
diagnosis of FH.4
A logical next step is to initiate cascade 
testing of relatives of index cases to help 
identify those with possible FH, as half the 
first-degree relatives would be expected to 
have the condition. A subsequent shared-
care approach involving support from lipid 
specialists and GPs can be used to help with 
intensive management of difficult-to-treat 
patients with FH.12
Cascade testing
The use of cascade testing relatives of index 
cases (Figure 3) in the detection of FH in 
tertiary centres has been based on meas-
uring plasma LDL-c levels and genetic 
testing, followed by treatment with statins. 
This is a cost-effective means to prevent 
CAD in an Australian setting,18 but fewer 
than 6% of all patients seen in primary care 
are referred for specialist care.19 The cost of 
genetic testing relatives of index cases would 
be prohibitive. The application of the 
DLCNC score to detect possible, probable 
and definite adult FH index cases is more 
feasible and cost-effective with LDL-c meas-
urements appropriate for  cascade testing 
children and adult relatives.4 
Active involvement of the primary care 
team (GPs, practice nurses and nurse prac-
titioners) could improve the detection of 
FH in the community, but cascade testing 
relatives may pose significant problems.20 
The Netherlands’ success with FH detec-
tion centred on the use of dedicated field 
workers to undertake family contact trac-
ing based on index cases. The opportuni-
ties to achieve similar improvement in the 
Australian setting do exist, but the impact 
of migration coupled with vastly different 
population densities in the two countries 
need to be considered. 
An integrated approach
Primary care through ease of access and 
frequent patient consultations offers poten-
tial to improve on current detection rates. 
Health promotion campaigns could increase 
awareness while pathology  laboratory high-
lighting of elevated LDL-c levels15 together 
with developing family pedigrees would be 
useful elements for a proactive approach. 
Commitment from the primary care team 
will be vital, as imposing additional time, 
manpower or financial burden on practices 
is likely to prove unsustainable. Building the 
infrastructure and knowledge base from 
within the practice offers the best long-term 
option for success.
Stratification of patients with FH into 
low, intermediate or high complexity (see 
the flowchart) can help GPs determine 
those patients who may benefit from 
 specialist help if needing more intensive 
management.12 The UK NICE guidelines 
have recognised the difficulties of under-
taking cascade screening from primary 
care and have suggested the use of special-
ist lipid clinics to undertake the work 
instead.11 The DLCNC score can be 
employed accurately in primary care21 and 
offers a better chance of success. 
Figure 1. Extensor tendon xanthomas. Figure 2. Corneal arcus.
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Consent
Consent and collaboration from index 
cases to approach relatives and inform 
them of their risk of FH is critical in the 
cascade testing process.20,22 Extensive evi-
dence shows this method to be clinically2,4,11 
and financially18,23,24 effective. Approaches 
to perform cascade testing in primary care 
incorporating risk notification have been 
suggested.4
Relatives who are also patients of the 
same practice as the index case should be 
encouraged to undertake LDL-c testing as 
part of their own regular health checks 
and advised accordingly. Other relatives, 
who are not patients of the practice, should 
ideally be advised by the index case of their 
potential FH risk and have LDL-c testing 
undertaken locally.
If the index case does not consent to 
cascade testing, the doctor should respect 
their decision and any subsequent disclo-
sure of medical information should occur 
only in exceptional circumstances in line 
with local health services protocols or 
National Health and Medical Research 
Council guidelines. When families and 
index cases agree to co-operate, it is essen-
tial that patient privacy and autonomy are 
respected and information concerning 
the nature of FH is given so that it can be 
easily understood and undue concern 
avoided.20
Similarly, consultations with relatives 
should involve pretest counselling to 
ensure such patients have a good under-
standing of the nature of FH. They should 
be given an uncomplicated explanation as 
to why early detection for themselves and/
or their children might be undertaken as 
well as reasons for treatment if they are 
shown to have FH. It is likely that a blood 
test and clinical examination will be ade-
quate to diagnose FH in primary care. 
Good communication skills and knowl-
edge of the patient and their family back-
ground should make the process easier for 
primary care teams. Having a specific 
doctor and nurse with an interest and skills 
in FH detection and management at a 
particular practice is likely to improve the 
sustainability of this process.
Management
A strategy of combining effective patient 
counselling on the nature of FH and on 
the importance of lifelong therapy is essen-
tial. Regular patient contact can ensure 
good compliance with medications, diet, 
exercise and other lifestyle modifications. 
High on the list of priorities would be 
smoking cessation, and other family mem-
bers in their immediate household should 
be similarly advised. Other risk factors for 
CAD disease, such as obesity, hypertension 
and diabetes, also need to be  adequately 
controlled. Suggested treatment targets 
start with a 50% reduction from baseline 
LDL-c levels, whereas levels under 3 mmol/L 
and 2 mmol/L are advisable for those 
requiring more aggressive or intensive 
management. 
There is increasing awareness that 
 lipoprotein(a) [Lp(a)], an independent, 
inherited risk factor for CAD, may also 
contribute to the variability in incidence 
of CAD in FH. Consequently, patients 
with FH who have elevated Lp(a) may 
require more aggressive lowering of 
 LDL-c, with aspirin indicated for those 
without symptomatic CAD.
Liver and kidney function tests together 
with creatine kinase measurement should 
be performed before patients commence 
lipid-lowering medication. Such baseline 
measurements are useful for future com-
parisons, especially if patients complain 
of myalgia or other symptoms subsequent 
to the start of statin therapy.
Rural GPs are often considerably disad-
vantaged by their geographical distance 
from specialist lipid colleagues. The use of 
the DLCNC score to achieve a phenotypic 
diagnosis can facilitate local assessment and 
enable risk stratification without relying on 
DNA genetic testing at a specialist centre. 
Specialist advice should be sought for 
patients requiring enhanced or intensive 
management (see the flowchart). The 
greater local community knowledge by GPs 
of index cases and their extended families 
facilitates cascade testing of relatives, while 
the construction of family pedigrees (Figure 
3) can help increase broader community
awareness of FH risk.
Women of childbearing age with FH 
should be adequately counselled about 
the risks of statin treatment in pregnancy, 
and advised to stop this therapy for at least 
three months before conception. For 
patients with FH who are at a particularly 
increased risk of CVD, the advice of a lipid 
specialist or cardiologist should be sought 
to enable a more comprehensive assess-
ment to be undertaken.
In children and adolescents, a key focus 
should be a low saturated fat, heart-healthy 
Figure 3. Pedigree tree diagram depicting dominantly inherited phenotype in a family. This is 
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diet; exercise; and lifestyle modifications, 
especially avoidance of smoking. Risk strat-
ification can help with approaches to treat-
ment but the importance and need for 
 lifetime treatment must be stressed and 
reinforced. Statins such as simvastatin, 
pravastatin and fluvastatin are licensed for 
use in children in Australia, but the safety 
and efficacy of rosuvastatin in children has 
not been established. Full details on age 
groups and approved indications are pro-
vided in each products prescribing informa-
tion, which should be consulted. If primary 
care physicians have concerns about initiat-
ing statin treatment or want additional guid-
ance for this age group, they may wish to 
seek advice and support from lipid specialists 
and/or paediatric cardiologists. As with 
adults, baseline measurements of liver and 
kidney function as well as the creatine kinase 
level are advisable. Other developmental 
aspects including growth patterns, body 
weight and sexual and physical maturation 
should also be monitored regularly.
Other siblings and first-degree relatives 
have a 50% chance of having FH and in such 
circumstances it may be possible to arrange 
for management and follow up of a family 
cluster at a specialised FH clinic either in 
primary care or at a tertiary clinic. For those 
patients requiring more intensive manage-
ment, the option of expensive LDL-apheresis 
where available or newer medications needs 
to be considered and advice sought from a 
lipid specialist. Such patients include those 
who are homozygous or compound hete-
rozygous as well as those refractory to or 
intolerant of  cholesterol lowering medica-
tions. The management of patients with 
severe FH – i.e. homozygous FH or hetero-
zygous FH with progressive CAD – should 
be undertaken at specialist lipid centres.6,25
Conclusion
FH is currently under-recognised and under-
treated in Australia. There is increasing 
interest in involving primary care teams to 
facilitate earlier diagnosis of index cases and 
to develop a sustainable approach to cascade 
testing relatives. The ease of access and 
 frequent patient contact are likely to facilitate 
this process in primary care. Increasing 
awareness among GPs, nurse practitioners, 
practice nurses and primary care teams is 
likely to increase the detection rate and treat-
ment within primary care. Newly diagnosed 
younger patients with FH can be assured of 
a normal life expectancy provided they 
adhere to treatment guidelines with medi-
cations and lifestyle modifications.   MT
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FAMILIAL HYPERCHOLESTEROLAEMIA continued 
SUGGESTED STRATIFICATION AND MANAGEMENT ALLOCATION STRATEGY FOR ADULTS DIAGNOSED WITH FH
Abbreviations: CVD = cardiovascular disease; FH = familial hypercholesterolaemia; LDL = low density lipoprotein.
Clinical assessment
Adult diagnosed with FH
Intensive management
Review interval: less than 6 months
Low complexity
No other major CVD risk factors, no 
symptomatic or subclinical CVD
Intermediate complexity
One or more other major CVD risk 
factors, early subclinical CVD
High complexity
Symptomatic CVD, revascularisation, 
advanced subclinical CVD
Treatment targets
Plasma LDL-cholesterol <4.0 mmol/L
Standard management
Review interval: 12 months
General practitioner care
Enhanced management
Review interval: 6 months
Treatment targets
Plasma LDL-cholesterol <3.0 mmol/L
Treatment targets
Plasma LDL-cholesterol <2.0 mmol/L
Specialist careShared care
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